SOURCE: MedinCell

MedinCell

November 22, 2011 11:45 ET

MedinCell Highlights Controlled-Release Strategy as Patent Cliff Bridge at Windhover Therapeutic Area Conference

MONTPELLIER, FRANCE and SAN DIEGO, CA--(Marketwire - Nov 22, 2011) - MedinCell will be meeting with pharmaceutical decision makers at the Windhover Therapeutic Area Conference in Boston (November 30-Dec 2, 2011) to discuss controlled-release strategies for drug life cycle management.

With formulation facilities in Montpellier, France, and San Diego, USA, MedinCell has experience in formulating molecules for each of the conference focus areas; neuroscience, autoimmune disorders, inflammation and oncology. Sebastien Enault, Pharmaceutical Business Development Director for MedinCell SA, explained, "MedinCell recently showcased candidate schizophrenia formulations tested in animal models that demonstrated therapeutic plasma levels of risperidone lasting 2 weeks, 1 month and 3 months. The ability to design a broad suite of treatment options with a single technology represents a competitive differentiator for life cycle management of high revenue drugs." Enault continued, "By improving patient compliance -- and at the same time reducing materials costs -- our partners can protect marketshare from generics while extending the lifespans of their key pharmaceutical brands."

Dr. Anh Nguyen, MedinCell Founder and CEO, explained, "While today's top pharmaceutical companies execute only a handful of partnerships out of the thousands they evaluate each year, MedinCell has grown steadily for the past five years exclusively through proof-of-concept programs and licensing revenues. By avoiding near-sighted venture investment, we have been able to establish best-in-class formulation programs and coordinate long-ranging supply chain partnerships in preparation for clinical programs. Additionally, our low materials costs and production simplicity make sustained-release of peptide and small molecule APIs highly feasible for emerging global markets," he concluded.

"As a proprietary polymer technology, MedinGel forms a biodegradable, subcutaneous depot that can be finely tuned to control initial drug burst, release profile and injection comfort," explained Dr. George Gaudriault, CSO for MedinCell. "MedinGel's inherent flexibility allows us to find a delivery solution for a wide range of molecules, and even opens up the potential for delivering API combinations for greater treatment flexibility," he added.

To fully understand how MedinCell develops sophisticated formulations for both NCEs and drugs that are closer to patent expiration, please contact Sebastien Enault (sebastien.enault@medincell.eu) to discuss delivery strategies at the Windhover event (http://www.tapartnerships.com), or to schedule a presentation for your R&D and formulation teams. We look forward to reinventing your next blockbuster for global markets.

About MedinCell

The patent-pending MedinGel technology limits the initial release of drug molecules to reduce off-target effects and extend release duration. This also means that Medincell's formulations require substantially less API quantities, which can be a pivotal consideration for many markets. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available at www.medincell.com.

Contact Information

  • Press contact:
    Christopher Hoover
    MedinCell Corporation
    10451 Roselle St, Suite 200
    San Diego CA 92121 USA
    +1 (858) 216-4573 phone
    Email Contact